ArticleJournal of bone oncology2024

BMS-794833 reduces anlotinib resistance in osteosarcoma by targeting the VEGFR/Ras/CDK2 pathway.

Qingtao Meng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.